Orion publishes Interim Report for January–March 2024 and holds a webcast on 25 April 2024
11 Avril 2024 - 8:30AM
Orion publishes Interim Report for January–March 2024 and holds a
webcast on 25 April 2024
ORION CORPORATION PRESS RELEASE 11 APRIL 2024 at 9.30 EEST
Orion publishes Interim Report for January–March 2024
and holds a webcast on 25 April 2024
Orion will publish Interim Report for January–March 2024 on
Thursday, 25 April 2024 at approximately 12.00 noon EEST. The
release and related presentation material will be available on the
company’s website at www.orion.fi/en/investors after
publishing.
Webcast and conference call
A webcast and a conference call for analysts, investors and
media representatives will be held on Thursday, 25 April 2024 at
13.30 EEST.
A link to the live webcast is available on Orion's website
at www.orion.fi/en/investors. A recording of the event will be
available on the website later the same day.
Confenrence call can be joined by registering through the
following link:
http://palvelu.flik.fi/teleconference/?id=10011670
Phone numbers and the conference ID to access the conference
will be provided after the registration. In case you would like to
ask a question during the conference, please dial *5 on your
telephone keypad to enter the question queue.
Questions can also be presented in writing through the question
form of the webcast.
Silent period
The silent period preceding the publication is ongoing and
continues until the disclosure.
Contact
person:Tuukka Hirvonen, Investor Relations, Orion
Corporationtel. +358 10 426 2721
Publisher:Orion
CorporationCommunicationsOrionintie 1A, FI-02200 Espoo,
Finlandwww.orion.fi
Orion is a globally operating Finnish pharmaceutical company – a
builder of well-being. We develop, manufacture and market human and
veterinary pharmaceuticals and active pharmaceutical ingredients.
Orion has an extensive portfolio of proprietary and generic
medicines and consumer health products. The core therapy areas of
our pharmaceutical R&D are oncology and pain. Proprietary
products developed by Orion are used to treat cancer, neurological
diseases and respiratory diseases, among others. Orion's net sales
in 2023 amounted to EUR 1,190 million and the company had about
3,600 employees at the end of the year. Orion's A and B shares are
listed on Nasdaq Helsinki.
Orion (BIT:1ORNBV)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Orion (BIT:1ORNBV)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024